Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Zentalis Pharmaceuticals (ZNTL) Return on Equity (2022 - 2025)

Historic Return on Equity for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to 0.57%.

  • Zentalis Pharmaceuticals' Return on Equity fell 800.0% to 0.57% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.57%, marking a year-over-year decrease of 800.0%. This contributed to the annual value of 0.43% for FY2024, which is 2100.0% up from last year.
  • Per Zentalis Pharmaceuticals' latest filing, its Return on Equity stood at 0.57% for Q3 2025, which was down 800.0% from 0.57% recorded in Q2 2025.
  • Zentalis Pharmaceuticals' 5-year Return on Equity high stood at 0.46% for Q1 2024, and its period low was 0.71% during Q1 2025.
  • Moreover, its 4-year median value for Return on Equity was 0.54% (2023), whereas its average is 0.54%.
  • In the last 5 years, Zentalis Pharmaceuticals' Return on Equity soared by 1200bps in 2024 and then crashed by -2500bps in 2025.
  • Over the past 4 years, Zentalis Pharmaceuticals' Return on Equity (Quarter) stood at 0.51% in 2022, then dropped by -17bps to 0.6% in 2023, then increased by 20bps to 0.48% in 2024, then decreased by -18bps to 0.57% in 2025.
  • Its last three reported values are 0.57% in Q3 2025, 0.57% for Q2 2025, and 0.71% during Q1 2025.